Beam Therapeutics Inc. (BEAM)

NASDAQ: BEAM · IEX Real-Time Price · USD
63.69
+0.26 (0.41%)
Aug 8, 2022 4:00 PM EDT - Market closed
0.41%
Market Cap 4.48B
Revenue (ttm) 60.27M
Net Income (ttm) -238.29M
Shares Out 70.27M
EPS (ttm) -3.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,077,457
Open 64.80
Previous Close 63.43
Day's Range 61.32 - 65.47
52-Week Range 27.77 - 116.91
Beta 1.76
Analysts Buy
Price Target 93.19 (+46.3%)
Earnings Date Aug 8, 2022

About BEAM

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Dise... [Read more...]

Industry Biotechnology
IPO Date Feb 6, 2020
Employees 394
Stock Exchange NASDAQ
Ticker Symbol BEAM
Full Company Profile

Financial Performance

In 2021, BEAM's revenue was $51.84 million, an increase of 215,916.67% compared to the previous year's $24,000. Losses were -$370.64 million, 90.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price forecast is 93.19, which is an increase of 46.32% from the latest price.

Price Target
$93.19
(46.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results

Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 On-track for Second Half of 2022

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $10...

Los Angeles, California--(Newsfile Corp. - August 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beam ...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,0...

Los Angeles, California--(Newsfile Corp. - August 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beam ...

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?

Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted the...

Other symbols: ALNYCRSPNTLA

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to C...

LOS ANGELES--(BUSINESS WIRE)---- $BEAM #BEAM--The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to...

Los Angeles, California--(Newsfile Corp. - August 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Beam ...

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Co...

LOS ANGELES--(BUSINESS WIRE)---- $BEAM #BEAM--The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm

Why Beam Therapeutics Stock Dipped Today

A clinical hold is weighing on the biotech's shares today.

Beam Therapeutics (BEAM) Stock Drops 4% on Clinical Hold News

Source: Natali_ Mis/ShutterStock.com Beam Therapeutics (NASDAQ: BEAM ) stock is slipping on Monday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on one of its drugs. According...

FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapses

The Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple. The post FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapse...

Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that on Fr...

Why Did BMO Capital Markets Raise Price Target For Gene Stock One Month After Initiating Coverage

BMO Capital Markets has raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $61 from $41, with a Market Perform rating unchanged. The model changes include updated collaboration revenues ...

The 3 Leaders of the Gene Editing Revolution

There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. The post The 3 Leaders of the Gene Editing Revolution appeared fir...

Other symbols: EDITVRTX

7 Moonshot Investments Upending a $10 Trillion Industry

Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on I...

Have $1,000 to Invest? 2 Stocks to Buy Right Now That Could Help Make You a Fortune

These two stocks could generate life-changing gains for patient shareholders.

Other symbols: AMC

A Comprehensive Guide to Genomic ETFs

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

Beam Therapeutics to Present First Research Highlighting Approach to Develop Non-Genotoxic Conditioning Regimens for ...

CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new r...

Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?

Beam Therapeutics Inc. (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ: BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation ...

5 Health Care Stocks Cathie Wood Favors

Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.

Other symbols: CRSPEXASNTLATDOC

3 Cathie Wood Stocks That Could Deliver Monster Returns

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

Other symbols: RXRXTXG

Beam Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John ...

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 8.18% and 89.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results

BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022

Beam Therapeutics to Participate in Upcoming May Investor Conferences

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John E...